Efficacy and safety of oral direct factor Xa inhibitors versus warfarin in patients with atrial fibrillation: A meta-analysis of randomized controlled trials

Acta Cardiologica

Volumn 71, Issue 3, 2016, Pages 349-357

  Xiang, Chun Lin ^a   Gong, Yi Zhen ^a   Zeng, Long Jia ^a   Wang, Rong ^a   Kea, Sok ^a   Chaudhary, Nabin ^a   Tu, Rong Hui ^a   He, Yan ^a  

^a FIRST AFFILIATED HOSPITAL OF GUANGXI MEDICAL UNIVERSITY   (China)

Author keywords

Atrial fibrillation; Bleeding; Oral direct factor Xa inhibitor; Stroke; Warfarin

Indexed keywords

BLOOD CLOTTING FACTOR 10A INHIBITOR; WARFARIN; ANTICOAGULANT AGENT;

ACUTE HEART INFARCTION; ARTICLE; ATRIAL FIBRILLATION; BLEEDING; BRAIN HEMORRHAGE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; GENETIC HETEROGENEITY; HEART MUSCLE ISCHEMIA; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; MORTALITY RATE; OUTCOME ASSESSMENT; PHARMACOKINETIC PARAMETERS; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; THROMBOEMBOLISM; COMPLICATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); STROKE;

ANTICOAGULANTS; ATRIAL FIBRILLATION; FACTOR XA INHIBITORS; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STROKE; WARFARIN;

EID: 84974855163     PISSN: 00015385     EISSN: 03737934     Source Type: Journal    
DOI: 10.2143/AC.71.3.3152095     Document Type: Article

References (37)

1. Lau YC, Lip GYH. New advances in the treatment of atrial fibrillation: focus on stroke prevention. Expert Opin Pharmacother 2014; 15: 2193-204.
2. Cheng JW, Barillari G. Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions. J Clin Pharm Ther 2014; 39: 118-35.
3. Palladino M, Merli G, Thomson L. Evaluation of the oral direct factor Xa inhibitor-betrixaban. Expert Opin Investig Drugs 2013; 22: 1465-72.
4. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007; 146: 857-67.
5. Connolly SJ, Eikelboom J, O’Donnell M, Pogue J, Yusuf S. Challenges of establishing new antithrombotic therapies in atrial fibrillation. Circulation 2007; 116: 449-55.
6. van Walraven C, Jennings A, Oake N, Fergusson D, Forster AJ. Effect of study setting on anticoagulation control: a systematic review and metaregression. Chest 2006; 129: 1155-66.
7. Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, Waldo AL, Ezekowitz MD, Weitz JI, Spinar J, Ruzyllo W, Ruda M, Koretsune Y, Betcher J, Shi M, Grip LT, Patel SP, Patel I, Hanyok JJ, Mercuri M, Antman EM. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013; 369: 2093-104.
8. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KA, Califf RM. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365: 883-91.
9. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FW, Zhu J, Wallentin L. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365: 981-92.
10. Bruins Slot KM, Berge E. Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation. Cochrane Database Syst Rev 2013; 8: CD008980.
11. Apostolakis S, Lip GY. Novel oral anticoagulants: focus on the direct factor Xa inhibitor darexaban. Expert Opin Investig Drugs 2012; 21; 1057-64.
12. Higgins JP, Altman DG, Sterne JAC, eds. Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S, eds. Cchrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration; 2011. http://www.cochranehandbook.org. Assessed 1 May 2012.
13. Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, Savovic J, Schulz KF, Weeks L, Sterne JA; Cochrane Bias Methods Group; Cochrane Statistical Methods Group. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ (Clinical research ed) 2011; 343: d5928.
14. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ (Clinical research ed) 2003; 327: 557-60.
15. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-88.
16. Song F, Eastwood AJ, Gilbody S, Duley L, Sutton AJ. Publication and related biases. Health Technol Assess 2000; 4: 1-115.
17. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 2009; 151: 264-69.
18. Turpie AGG, Lip GYH, Minematsu K, Goto S, Renfurm RW, Wong KSL. Safety and tolerability of YM150 in subjects with non-valvular atrial fibrillation: a phase II study.Eur Heart J 2010; 31 Suppl 1: 173.
19. Lip GYH, Halperin JL, Petersen P, Rodgers GM, Renfurm RW. Safety and tolerability of the oral factor Xa inhibitor, YM150 vs. warfarin in 1297 patients with nonvalvular atrial fibrillation: a dose confirmation study (OPAL-2). J Thromb Haemost 2011; 9 Suppl 2: 748.
20. Ezekowitz MD. A phase 2, randomized, parallel group, dose-finding, multicenter, multinational study of the safety, tolerability and pilot efficacy of three blinded doses of the oral factor Xa inhibitor betrixaban compared with open-label dose-adjusted warfarin in patients with non-valvular atrial fibrillation (EXPLORE-Xa). American College of Cardiology 59th Annual Scientific Sessions in Atlanta, GA, March 15, 2010. Available from: http://assets.cardiosource.com/ezekowitz_explore1.ppt#636,1,EXPLORE-Xa.
21. Connolly SJ, Eikelboom J, Dorian P, Hohnloser SH, Gretler DD, Sinha U, Ezekowitz MD. Betrixaban compared with warfarin in patients with atrial fibrillation: results of a phase 2, randomized, dose-ranging study (Explore-Xa). Eur Heart J 2013; 34: 1498-505.
22. Yamashita T, Koretsune Y, Yasaka M, Inoue H, Kawai Y, Yamaguchi T, Uchiyama S, Matsumoto M, Ogawa S. Randomized, multicenter, warfarin-controlled phase II study of edoxaban in Japanese patients with non-valvular atrial fibrillation. Circ J 2012; 76: 1840-7.
23. Weitz JI, Connolly SJ, Patel I, Salazar D, Rohatagi S, Mendell J, Kastrissios H, Jin J, Kunitada S. Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation. Thromb Haemost 2010; 104: 633-41.
24. Chung N, Jeon HK, Lien LM, Lai WT, Tse HF, Chung WS, Lee TH, Chen SA. Safety of edoxaban, an oral factor Xa inhibitor, in Asian patients with non-valvular atrial fibrillation. Thromb Haemost 2011; 105: 535-44.
25. Ogawa S, Shinohara Y, Kanmuri K. Safety and efficacy of the oral direct factor xa inhibitor apixaban in Japanese patients withnon-valvular atrial fibrillation. -The ARISTOTLE-J study. Circ J 2011; 75: 1852-9.
26. Hori M, Matsumoto M, Tanahashi N, Momomura S, Uchiyama S, Goto S, Izumi T, Koretsune Y, Kajikawa M, Kato M, Ueda H, Iwamoto K, Tajiri M; J-ROCKET AF study investigators. Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation - the J-ROCKET AF study. Circ J 2012; 76: 2104-11.
27. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001; 285: 2864-70.
28. Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, Camm AJ, Weitz JI, Lewis BS, Parkhomenko A, Yamashita T, Antman EM. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomsed trials. Lancet 2014; 383: 955-62.
29. Jia B, Lynn HS, Rong F, Zhang W. Meta-analysis of efficacy and safety of the new anticoagulants versus warfarin in patients with atrial fibrillation. J Cardiovasc Pharmacol 2014; 64: 368-74.
30. Stroke Risk in Atrial Fibrillation Working Group. Independent predictors of stroke in patients with atrial fibrillation: a systematic review. Neurology 2007; 69: 546-54.
31. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010; 138: 1093-100.
32. Go AS, Fang MC, Udaltsova N, Chang Y, Pomernacki NK, Borowsky L, Singer DE; ATRIA Study Investigators. Impact of proteinuria and glomerular filtration rate on risk of thromboembolism in atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Circulation 2009; 119: 1363-69.
33. Piccini JP, Stevens SR, Chang Y, Singer DE, Lokhnygina Y, Go AS, Patel MR, Mahaffey KW, Halperin JL, Breithardt G, Hankey GJ, Hacke W, Becker RC, Nessel CC, Fox KA, Califf RM; ROCKET AF Steering Committee and Investigators. Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) study cohorts. Circulation 2013; 127: 224-32.
34. Hughes M, Lip GY; Guideline Development Group, National Clinical Guideline for Management of Atrial Fibrillation in Primary and Secondary Care, National Institute for Health and Clinical Excellence. Stroke and thromboembolism in atrial fibrillation: a systematic review of stroke risk factors, risk stratification schema and cost effectiveness data. Thromb Haemost 2008; 99: 295-304.
35. Greinacher A, Thiele T, Selleng K. Reversal of anticoagulants:an overview of current developments. Thromb Haemost 2015; 113: 931-42.
36. Mega JL. A new era for anticoagulation in atrial fibrillation. N Engl J Med 2011; 365: 1052-4.
37. Cabral KP, Ansell J, Hylek EM. Future directions of stroke prevention in atrial fibrillation: the potential impact of nove anticoagulants and stroke risk stratification. J Thromb Haemost 2011; 9: 441-9.